Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Silexion TherapeuticsSLXN +0.73%13 Debt-to-Equity is 9.66 as of Jun. 2026, which is 6800% above its 10-year median of 0.14. GuruFocus rates SLXN with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 961 Biotechnology companies, Silexion Therapeutics ranks worse than 98.96% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Silexion Therapeutics's Debt-to-Equity or its related term are showing as below:
SLXN'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.13 Med: 0.14 Max: 30.82
Current: 9.66
During the past 4 years, the highest Debt-to-Equity Ratio of Silexion Therapeutics was 30.82. The lowest was -1.13. And the median was 0.14.
SLXN's Debt-to-Equity is ranked worse than 98.96% of 961
companies
in the Biotechnology industry
Industry Median: 0.16
vs SLXN: 9.66
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Silexion Therapeutics Debt-to-Equity Related Terms
Silexion Therapeutics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Silexion Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SLXN vs DCOY, VRAX, PTIX: Debt-to-Equity Comparison
For the Biotechnology subindustry, Silexion Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Silexion Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Silexion Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Silexion Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Silexion Therapeutics (SLXN) has a Debt-to-Equity of 9.66 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Silexion Therapeutics and its competitors. This is 6800% above median its historical median of 0.14. According to the industry distribution chart, Silexion Therapeutics ranks #951 out of 961 companies in the Biotechnology industry, placing it in the top 99%.
Is Silexion Therapeutics' Debt-to-Equity too high?
Silexion Therapeutics' current Debt-to-Equity of 9.66 is 6800% above median its 10-year median of 0.14. The Biotechnology industry median Debt-to-Equity is 0.16. Silexion Therapeutics' value of 9.66 is 5937.5% above this industry median. Based on the distribution chart, Silexion Therapeutics ranks #951 out of 961 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Silexion Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Silexion Therapeutics' Debt-to-Equity compare to DCOY and VRAX?
According to the Biotechnology industry distribution chart, Silexion Therapeutics ranks #951 out of 961 companies for Debt-to-Equity. This places Silexion Therapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Silexion Therapeutics' value of 9.66 is 5937.5% above this benchmark. While the company's 10-year median is 0.14 vs. the industry median of 0.16, Silexion Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Silexion Therapeutics's current Debt-to-Equity of 9.66 is 5937.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Silexion Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Silexion Therapeutics's current Debt-to-Equity is 9.66, which is 6800% above median its own 10-year median of 0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Silexion Therapeutics stock overvalued right now?
Silexion Therapeutics (SLXN) has a current Debt-to-Equity of 9.66. The current Debt-to-Equity is 9.66, which is 6800% above median its 10-year median of 0.14 and 5937.5% above the Biotechnology industry median of 0.16. Silexion Therapeutics' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Silexion Therapeutics (SLXN), the current Debt-to-Equity is 9.66 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Its proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while maintaining biological activity that interferes with the mRNA function. Its product candidate, SIL204, is a second-generation siRNA engineered to suppress the production of mutated KRAS proteins.
13GF Score
Get the complete analysis for SLXN
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLXN has been successfully added to your 
